Aarti Pharmalabs Limited · NSE:AARTIPHARM
Aarti Pharmalabs — Q3 FY2024 Earnings Presentation
26 slides from Aarti Pharmalabs's earnings presentation
Slide 1: Aarti Pharmalabs Limited Q3 FY24 Results Presentation
Aarti Pharmalabs Limited Q3 FY 24 Results Presentation
Slide 2: Disclaimer
Disclaimer AARTI PHARMALABS LIMITED may, from time to time, make written and oral forward looking statements, in addition to statements contained in the company's filings with BSE Limited [BSE] and National Stock Exchange of India Limited [NSE], and our reports to shareholders. The company does not u
Slide 3: Index
Index 1 Company Overview 2 Financial Performance 3 APL Growth Strategies
Slide 4: Company Overview
Company Overview
Slide 5: Aarti Pharmalabs at a Glance
Aarti Pharmalabs at a Glance Overview FY 23-24 Q3 - Consolidated Revenue Breakup (Rs Cr) ▪ Established by first generation technocrats in 1984 ▪ Specialized key business verticals ■ API & Intermediates, ■ CDMO & CMO Services ■ Xanthine derivatives & allied ▪ Strong R&D capabilities with IPRs for cust
Slide 6: Journey
Journey Expanded block •Unit 5 commissioned for CSD, Vapi and for Caffeine Production Oncology block API, Tarapur. with a capacity of 100 at Unit 4 Commissioning of first 1st Clearance of the Oncology block at MT per month audited by Acquired Land at Incorporated API manufacturing Unit USFDA & EUGMP
Slide 7: Manufacturing Facilities
Manufacturing Facilities Unit - II Custom synthesis Manufacturing Location division (CSD) Units Location: Vapi Dombivali Unit - I (API & Intermediates) R&D Centers Unit - II (API Intermediates & Vapi Location: Vapi, Custom Synthesis Unit) Unit – III (Xanthine Unit) Gujarat Dombivali Greenfield Proje
Slide 8: Key Business Verticals
Key Business Verticals APIs and Intermediates CDMO / CMO Services Xanthine derivatives & Allied (Caffeine and others) ❏ US FDA approved manufacturing facility ❏ CRAMs activity focused on API & intermediates ❏ Largest Indian Manufacturer for ❏ Exports to lucrative regulated markets - US, EU and Japan
Slide 9: Key Business Verticals
Key Business Verticals CMO CDMO 14.2% Xanthine& Others 48.9% API & Intermidates AARTI PHARMALABS
Slide 10: Strong Presence in API & Intermediates
Strong Presence in API & Intermediates 54 13 41 21 ~100 APIs have been New APIs are under US DMF approvals CEP approvals Generic Intermediates commercialized by APL development at APL’s obtained across available for sale in are available at R&D, since it entered the dedicated R&D facility/ multiple
Slide 11: CDMO / CMO
CDMO / CMO ❏ Sustainable supply for APIs/NCEs/Intermediates in commercial scale ❏ Global regulatory accreditations (USFDA ,EUGMP, EDQM, KFDA, COFEPRIS) ❏ EHS and Quality are the highest priority. Facilities were audited as per PSCI principles ❏ High potent molecules (Oncology/Cytotoxic) development
Slide 12: Manufacturing Capabilities & Strengths
Manufacturing Capabilities & Strengths Impeccable Strong expertise in regulatory track Hydrogenation 20+ years of development of HPAPI (Cytotoxic/ record (>15 years) Backward facilities from lab Cryogenic reactors experience in robust & Oncology) and High temperature and facilities integration of ra
Slide 13: Xanthine Derivatives
Xanthine Derivatives • Xanthine derivatives are synthetic End Use Certifications compounds that resemble natural occurring xanthines such as caffeine etc., • Commonly used as mild stimulants & Cola Drinks Energy Drinks bronchodilators, notably in the treatment of asthma or influenza symptoms • 2 dedi
Slide 14: R&D Strengths & Capabilities
R&D Strengths & Capabilities 3 70+ 7 22 53 State-of-the-art R&D centres at Maharashtra & Scientists PHDs. Patents Granted Process patents filed Gujarat 150+ 50+ Process for more than 150 Intermediates developed More than 75 API and manufactured on kilo commercialized lab scale 160 39 crs Developing 4
Slide 15: Strong Focus on R&D & Process Innovation
Strong Focus on R&D & Process Innovation Innovation at various reactions ● Carbohydrate Chemistry ● Chiral Chemistry ○ Asymmetric Synthesis ○ Bio Catalysts ○ Chiral Epoxides ○ Kinetic Resolution ● Coupling Reactions Chemistry ○ C-C Coupling ○ C-N Coupling ● Isomerization Reactions ● Triphosgene Reac
Slide 16: ESG at APL
ESG at APL Environment - Highlights Social - Highlights Governance - Highlights ● ISO 14001 : 2015 certification ● Hazard Identification and Risk Assessment • Robust Compliance Monitoring (HIRA), Hazardous Area Classification Framework - implemented PWC’s ● All plants are Zero Liquid Discharge (HAC) an
Slide 17: Financial Performance
Financial Performance ………………………………………………..
Slide 18: Q3 FY24: Highlights (Consolidated)
Q3 FY24 : Highlights (Consolidated) Revenue from EBITDA Highlights of Q3 FY 24 operations INR 448 crs INR 97 crs 2.0% QoQ 9.1 % QoQ ❏ Q3 FY24 registerd highest ever EBIDTA till date. ❏ Revenues increased by 2% QoQ.. ❏ EBITDA on consolidated basis was PAT Domestic : Export higher by 9.1% Quarter on Q
Slide 19: Q3 FY24 Highlights (Consolidated)
Q3 FY24 Highlights (Consolidated) Revenues EBITDA Profit After Tax
Slide 20: Q3 FY24 Consolidated Profit & Loss
Key Performance Indicators Q3 FY24 – Consolidated Profit & Loss Particulars (Rs. Crore) Q3 FY24 Q2 FY24 Q-o-Q (%) Q3 FY23 Y-o-Y (%) Gross Income from Operations 449 440 2.0% 472 -4.9% Exports 228 198 15.1% 229 -0.3% % of Total Income 50.8% 45.0% 48.4% EBITDA 97 89 9.1% 87 12.2% EBITDA Margin (%) 21.
Slide 21: Q3 FY24 Standalone Profit & Loss
Key Performance Indicators Q3 FY24 – Standalone Profit & Loss Particulars (Rs. Crore) Q3 FY24 Q2 FY24 Q-o-Q (%) Q3 FY23 Y-o-Y (%) Gross Income from Operations 373 356 4.8% 359 3.9% Exports 203 172 18.0% 172 18.0% % of Total Income 54% 48% 48% EBITDA 88 74 19.9% 72.6 21.9% EBITDA Margin (%) 23.7% 20.
Slide 22: Q3 FY24 other highlights
Q3 FY 24 other highlights ➢ Highest ever EBDITA and net Profit in Q3 FY24. ➢ Interim dividend of Rs 2 per share. ➢ Revenue contribution of CDMO / CMO has grown to 14% (from 7% in Q2FY24 and 6% in Q3FY23). ➢ Sales to regulated market continues to remain the key area of focus. ➢ The work on the Greenfie
Slide 23: Growth Strategies
Growth Strategies ………………………………………………..
Slide 24: Our Growth Strategy
Our Growth Strategy ● ● Increase in capacities of existing products & Adding new 40+ Value added product each year. ● Further expansion in Xanthine Capacities. Atali Project ● ~ 80 acres of land in Gujarat (between Dahej & Bharuch) Growth Develop and explore more Initiatives under ● Adding 400+KL re
Slide 25: Outlook
Outlook ◆ Rampup of new expended blocks at Unit IV, Tarapur & Xanthine Derivatives FY24 ◆ Expected EBIDTA Growth to be about 8-10% over FY23. ◆ Commissioning of Blocks at Atali in phased manner from FY25. FY25 and ◆ Rampup @ Atali project will bring in operating leverages in FY26 and beyond beyond ◆
Slide 26: Thank You
THANK YOU Aarti Pharmalabs Limited #204, Udyog Kshetra, 2nd Floor, Mulund Goregaon Link Road, Mulund West, Mumbai - 400080, Maharashtra, India. Email: investorrelations@aartipharmalabs.com Contact: +91 22 67976666